Smoking Cessation: Essential Diabetes Care

International consensus recommendations now advocate for integrating smoking cessation into the routine management of type 2 diabetes. This approach is crucial as smoking exacerbates complications like cardiovascular disease, stroke, and poorer blood sugar control. The guidelines, developed by the DiaSmokeFree Working Group, propose a structured intervention combining counseling, medication, and relapse prevention. Varenicline is identified as a first-line medication, with nicotine replacement therapy and bupropion as alternatives, although further research is needed for their effectiveness specifically in type 2 diabetes patients.

Clinicians must also be aware that quitting smoking can alter drug metabolism, potentially requiring dose adjustments for certain medications. The period following cessation is critical, with recommendations for monitoring glycaemic control, blood pressure, and weight, and addressing potential weight gain proactively. Researchers are also exploring newer approaches, including the role of GLP-1 receptor agonists, but current evidence is insufficient for their establishment as standard cessation treatments.

Implementing these recommendations may pose challenges in low- and middle-income countries due to limited access to medications and structured programs. Task-shifting, cost-effective behavioral interventions, and integration into existing chronic disease services are suggested practical adaptations. The overall message is that smoking cessation should be treated as a vital clinical intervention for people with diabetes.